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Chapter II. Human Stem-cells 
research. Their relation with Patent 
Law49  
11.1. Introduction: The direct effects of patents on 
biotechnological research 
The question as whether patents that fall on basic 
biotechnological tools should or should not be public domain has 
been raised50, because many of the most important genetic research 
act as platforms or Iaunch pads to open areas of investigation. The 
patents of these basic resources are perceived as a point of 
49  Dr. Cecilia GÓMEZ-SÁNCHEZ SALVAGO. Professor of Civil Law. University of Seville. 
salvago@us.es  This work is the result of a research grant program "Estancias en centros 
extranjeros y excepcionalmente españoles, de profesores de Universidad e investigadores 
españoles, incluido el programa Salvador de Madariaga", in the Faculty of Law in 
University of Trento, in the "Biodiritto" program led by Prof. Carlo CASONATO 
(Resolution of 17 March 2009 of the Ministry of Universities, BOE, April 2). 
so 
Richard GOLD, Yann JOLY, Tomoyhy CAULFIELD: "Genetic Research Tools. The 
Research Exception and Open Scienze", in GenEdit, 2005, Vol III, No.2. From an ethical 
standpoint see Góran HERMERÉN: "How could the concepts of 'ordre public' and 
'morality' be Interpreted? What ethical considerations are relevant in the Patenting of 
Human DNA?" in "The ethics of human Patenting genes and stem cells. "Conference Report 
and Summaries. Held in Copenhagen 28 September 2004, Organized by The University of 
Copenhagen. The Danish Council of Ethics Biotika. www.biotik.dk/sw293.asp. (Published 
by The Danish Council of Ethics) 
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deceleration in investigative activity, because of increasing costs that 
delay the publication of the conclusions and suffocate the 
collaboration in this area of biomedicine51 . It is necessary to sustain 
non-commercial public investigation52 and to foment the politics of 
the sanitary research even though they fali over abnormal illnesses. 
From this perspective, the patent system produces two direct 
effects over biotechnological research: firstly, the difficulty of open 
access to the research and the technology, and secondly, the increase 
of sanitation costs53. To alleviate them one needs to play a decisive 
role, for example, the creation of registrations of unmodified stem 
cells lines, that included information about the embryonic stem cells, 
germs, and embryonic cells, that guarantee the transparency and 
facilitate access of the scientific community to the research, and in 
51  The negative consequences of patents in biomedical research, see Richard GOLD et al, 
Genetic Research Tools. The research Exception and open Scienze, op. cit., pp. 6 and 2. See 
also Thomas G. JENSEN: "What problems does Patenting pose to fundamental biomedical 
research-and possible solutions?, in The Ethics of Patenting human genes and stem cells." 
Conference Report and Summaries. Held in Copenhagen 28 September 2004, Organize by 
The University of Copenhagen. The Danish Council of Ethics Biotika. 
www.biotik.dk/sw293.asp  (Published by The Danish Council of Ethics). 
52  Thomas G. JENSEN, op. cit. See section 2 of the summary of the meeting. 
53  In this sense, Opinion No. 16 of the European Group on Ethics (EGE) referred to 
concerns that the overcharge would prevent access to health care. The EGE considers it 
essential, in addition to academic exemption, that patents are not too broad, as this could 
have adverse effects on the objective of supporting innovation in health benefits (EGE 
2002, p. 18, section 2.7). See Góran Hermerén, How could the concepts of "ordre public" 
and "morality" be I nterpreted? What ethical considerations are relevant in the Patenting of 
Human DNA? art. cit. 
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this way the necessity, world renowned, of public human embryonic 
stem cell banks54. Thirdly, with the ends of assuring that the titles of 
the patents don't have an abusive use of their rights through the cost 
of excessive fees, it should be fomented the resource of obligatory 
licenses, when access to the diagnostic and the treatment are blocked 
by the inappropriate use of the patents, allowing the equal access to 
sanitary attention when this process is justified. 
11.2. Patent of Human Embryonic Stem cells 
11.2.1. The status of the issue: The clause of public order 
In the period before the Directive 1998/44/CE about 
patentability of biotechnological inventions the problem had still not 
come up. European national regulations in this subject were 
coordinated by European patent Convention October 5th, 1973, 
ratified by Spain on July 10th, 1986. New events on biotechnological 
and genetic engineering were acquiring a growing function in the 
industrial activities. This placed Europe at a disadvantage in front of 
the USA and Japan55. 
54  In Spain the National Stem Cell Bank is attached to the General Office of Research on 
Cell Therapy and Regenerative Medicine of the Carlos III Health Institute. See 
http://www.isci  ii.es/htdocs/terapia/terapia_bancocelularjsp 
55  We refer in particular to the American patent application for the testing of oncogenes on 
mice, on 24 June 1985, which was granted on 12 April 1988. See GÓMEZ SEGADE, J. A.: 
"Decisión de la División de Examen de la Oficina Europea de Patentes de 3 de abril de 
1992", in Gómez Segade, Tecnología y Derecho. Estudios jurídicos del Prof. Dr. H.C., José 
Antonio Gómez Segade recopilados con ocasión de la conmemoración de los XXV años de 
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The first proposition, October 20th, 1988, signaled that live 
organisms could be patented. Nevertheless, it was criticized 
ferociously because of the lack of references to the ethical question. 
After a political battle, the result is a final text of a compromise 
between the diverse ethical opinions about the way to protect this 
delicate sector of discoveries and inventions56. 
The Directive 98/44, as the European internal regulations and 
the European Group of Ethics admit the patentability of the 
processes surrounding human stem cells, with general requirements 
(development, the inventive activities, and industrial application). If 
these requirements are not met the human stem cells cannot be 
patented. Under the budget if the stem cells have been invented, and 
cátedra, Madrid 2001, pp. 723 to 732. See also in the same work by the same author the 
following articles: "Patentes y bioética en la encrucijada: del onco-ratón al genoma 
humano" pp. 955-961; "Decisión de la Cámara de Recursos Técnica de la Oficina Europea 
de Patentes de 3 de octubre de 1990. Patentabilidad de los animales: el ratón transgénico", 
pp. 689-708. Besides this fact, there were many patent applications on the human genome 
in the USA and UK. The height of the crisis occurred in 1991 when the U.S. National 
Institute of Health (Criag Venter) applied for 3.000 patents on gene sequences with no 
known biological application, which caused the reaction of the UK's Medical Research 
Council to request, in turn, 1.000 patents. 
56  In this regard, certain statements contained in the preamble may provide guidance to 
understand the various interests at stage, -the patent holder to profit on the promotion of 
biotechnology research, and heaith and welfare of humanity-, and the difficulty of 
reconciling both of them in the rules of patents. 
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not simply discovered or found, nevertheless not all the human 
embryonic stem cells can be patented57. 
The Directive refers explicitly to the germinal cells in order to 
exclude them from the patentability, but there is nothing that is 
57  Article 3: "1. For the purposes of this Directive, inventions which are new, which involve 
an inventive step and which are susceptible of industrial application shall be patentable 
even if they concern a product consisting of or containing biological material or a process 
by means of which biological material is produced, processed or used. 2. Biological material 
which is isolated from its natural environment or produced by means of a technical process 
may be the subject of an invention even if it previously occurred in nature". 
Given these requirements, the Preamble 20 says: "Whereas, therefore, it should be made 
clear that an invention based on an element isolated from the human body or otherwise 
produced by means of a technical process, which is susceptible of industrial application, is 
not exciuded from patentability, even where the structure of that element is identical to 
that of a natural element, given that the rights conferred by the patent do not extend to the 
human body and its elements in their natural environment"; and 21: "Whereas such an 
element isolated from the human body or otherwise produced is not exciuded from 
patentability since it is, for example, the result of technical processes used to identify, 
purify and classify it and to reproduce it outside the human body, techniques which human 
beings alone are capable of putting into practice and which nature is incapabie of 
accomplishing by itself". Assuming that patent rights do not extend to the human body and 
its elements in their natural environment, the Preamble reaffirms that (16): "Whereas 
patent law must be applied so as to respect the fundamental principies safeguarding the 
dignity and integrity of the person; whereas it is important to assert the principie that the 
human body, at any stage in its formation or development, including germ cells, and the 
simple discovery of one of its elements or one of its products, including the sequence or 
partial sequence of a human gene, cannot be patented; whereas these principies are in line 
with the criteria of patentability proper to patent law, whereby a mere discovery cannot be 
patented". 
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written about embryonic stem cells. The question will be then if they 
can be patented without any ethical obstacle that would stop it58. 
The answer needs to be brought forth about Article 6.2 c) 
Directive 98/44, the public order clause, which excluded the 
patentability of inventions whose commercial exploitation would be 
contrary to public order or to the morality, and in particular, the uses 
of human embryos with commercial or industrial ends. This norm 
generates transcendent economic consequences in the European 
economic context, and also brings forth important problems with 
interpretation59. For example, if we make reference to the future acts 
of economic exploitation of the invention, or if the experimental acts 
that have preceded the request are understood; if we make reference 
to the use on the research of excess embryos, or also to the embryos 
created for the means of the investigation; if it makes sense to 
distinguish between the ends of the research or the 
58  Geertrui VAN OVERWALLE raises the question. "Patentability of human stem cells and 
cell lines", in "The Ethics of Patenting human genes and stem cells." Conference Report 
and Summaries. Held in Copenhagen 28 September 2004, Organized by The University of 
Copenhagen. The Danish Council of Ethics Biotika. www.biotik.dk/sw293.asp.  
59  Gerard PORTER, Chris DENNIGN, Aurora PLOMER, John SINDEN & Paul 
TORREMANS: "The patentability of human embryonic stem cell in Europe. Applicants in 
Europe are left CITH fez options for the patent of hES cell-related technology", in Nature 
Publishing 	Group 	2006, 	vol.24, 	No.6, 	June 	2006. 
http://www.nature.com/naturebiotechnoloy  Just think that as U.S. Patent and trademark 
Office has granted many patents claiming human embryonic stem cells in their titles 
(including the patent in the methods of differentiation of such cells), while the European 
Patent Office (EPO) does not grant patents claiming such cells. 
commercialization60; without forgetting to remember that 
complexities of the problem of how to define what an embryo 
actually is. 
Without coming to a finite closure, we can say now that 
inventions with human embryonic stem cells will be patentable if the 
employed method doesn't destroy them, in a strict sense, and if the 
ends are in accordance with the national regulations. So we will 
continue explaining these specific circumstances. 
11.2.2. Relevance of techniques of Embryonic Stem cells 
research as regards patentability of results 
It's a premise in the European context that the method to 
create the embryonic stem cells cannot destroy the cells, for the 
patentability of the invention61. To this effect, it's necessary to 
question if the term "commercial exploitation" used on art. 6.2 c) of 
the Directive and in the national patent laws, we make reference only 
for the future economic uses of the invention, or if the experimental 
so 
problems studied by Geertrui VAN OVERWALLE: "Patentability of human stem cells 
and cell lines", op.cit. www.biotik.dk/sw293.asp.  
61  This has been confirmed by the EPO in the WARF case. Distinctly the office has a very 
broad concept of embryo and has not clarified the meaning of the term. The procedure for 
making decisions that this office performs has been criticized. The procedure to certify that 
inventions do not violate public order or morality has been accused of irregularities; and 
that they should have been established by a group of experts in the field of ethics that could 
provide a clear and consistent jurisprudence. Richard GOLD and Alain GALLOCHAT, op. 
cit., p. 360. Patents are considered by people with little experience, although the topics to 
be addressed are very important, and can result in denial of the patent. 
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acts that have preceded the request of the patent are understood62. 
The subject has practical transcendences, because if it is the first 
case, the inventions could be patented when the development of the 
inventive activity is to be created illegally, although its repetition 
would not be necessary in order to commercially exploit the 
invention63; in the second case, if the development of the inventive 
activity were realized contrary to public order it could not be 
patented. 
The question is how far a patent which claims a product, such 
as an embryonic stem cell line may be withheld if the invention has 
been obtained through procedures that are contrary to the public 
order, although the procedure is not the subject of the claim. The 
EPO has given its answer, including under the blanket of public order 
(ex Art. 6.2.c) carrying out the invention of the claimed cell line64. 
62  It follows ROMANDI NI: "Comment to the Legge 22 febbraio 2006, n.78 sulle invenzioni 
biotecnologiche" in Marchetti-Ubertazzi, Commentario alle leggi brief intellettuale and its 
owner to concorrenza, 4th ed., Milano 2007, pp. 1367 et seq., op. cit., p. 1377. 
63  As examples, inventions improved by an illegally derivative of human biological material, 
violating the rules on informed consent, or through an act of biopiracy. 
64  This is the position of EPO of 25 November 2008, in the case WARF, G0002/06, which 
claimed a culture of human embryonic cells, which was rejected because the method 
described enveloped the destruction of embryos. See press release: http://www.epo-
org/about-us/press/releases/archieve/2008.html  See the comment that STERCKX made, 
"The Warf / Stem Cells before the EPO Enlarged Boad of Appeal", in European Intellectual 
Property Rewiew, Volume 30, Issue 12, 2008, pp. 535-537. See also on the topic GÓMEZ-
SALVAGO SÁNCHEZ: "El marco europeo de la protección juridical de los resultados de la 
investigación biomedical sobre clonación terapéutica: implicaciones para los investigadores 
andaluces", in Daniel GARCÍA SAN JOSÉ (ed.) Régimen jurídico de la investigación 
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But the problem is that the concept of "public order" does not exist 
for all the European states, except the preconception that is used by 
EPO. 
An example of a country that adopted this initial positioning 
was Belgium that with regard to the exemption of public order and 
morality was not confined to commercial exploitations and extended 
them to the inventions produced by means contrary to public order 
or morality65, however, present legislation in this country has been 
overtaken by a new one66. 
Another problematic situation arises when the invention has 
been initiated in accordance with the standards of a system but seeks 
to extend the exclusivity in the context of other domestic legislation, 
which is understood in another sense as the clause of "public order" 
and would cause the rejection of the claimed patent. Let us start with 
an example. The system in the United Kingdom, which allows the 
creation of embryos for research (for IVF and nuclear somatic 
biomédica en Andalucía. En el marco de la legislación nacional e internacional, ed. 
Laborum, 2009. 
65  Richard GOLD and Alian GALLOCHAR, op. cit., p. 350. They criticize these authors 
because they do not seem to fit neither the Directive nor the Trips agreement. 
66 At  present, the Law on research on human embryos in vitro (April 2003) expressly 
permits the derivation of HESTCs coming from the surplus embryos in vitro reproduction 
and the creation of human embryos for research using SCNT. See the overall picture 
available at www.stemcellconsortium.org  
49 
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transfer)67, and derives stem cells from surplus embryos for assisted 
reproduction, their Patent Office recognizes consistently, that the 
commercial exploitation of inventions concerning human embryonic 
pluripotent stem cells is not contrary to public order or morality68 in 
the UK. The achieved English patent would be rejected in Italy, 
because the Italian legislation prohibits the creation of embryos for 
research, including transfer nuclear somatic stem cells, and cell lines 
derived from human embryonic cells69. The same result would occur 
if the patent was requested in Austria, which also voted against 
research with human embryonic stem cells and maintains today the 
same regulation70. 
67  The Human Fertilization and Embryology (HFE) Act (2008). See 
http://www.opsi.gov.uk/acts/acts2008/ukpga_20080022_en_1 See also 
www.dh.gov.uk/en/Publicationsandstatistics/PublicationsLegislation/DH  080205 
68  http://www.i  po.gov.uk/pro_types/pro-  patent/P- law/p-Pn-stemcells-2009203.htm 
69  In the words of the Directive (14) "...patent law cannot serve to replace or render 
superfluous national, European or international law which may impose restrictions or 
prohibitions or which concerns the monitoring of research and of the use or 
commercialization of its results, notably from the point of view of the requirements of 
public health, safety, environmental protection, animal welfare, the preservation of genetic 
diversity and compliance with certain ethical standards". 
7°  We follow the overall picture provided by the International Consortium of Stem cell 
networks, available in www.stemcellconsortium.org. In the case of Austria refers to the 
following address on-line: www.ris.bka.gv.at  / Bundesrecht Designed is also used at the 
following web address: http://www.bionetonline.org/castellano/Content/sc_leg2.htm # Q2 
This table has been verified with the legal situation at present (February 2010). Also been 
taken into account the regulations offered at the following addresses: 
www.stemcellconsortium.org  (last entry 18 September 2008) 
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The disparity between member countries is a consequence of 
the freedom that applies to every state in the determination of rules 
that should govern the field of scientific research on stem cells 
(Oviedo Convention, art. 18). Consequently, the conflict is served, to 
be very different regulation of embryonic stem cell research in 
Europe. 
For example, in regard to the creation of embryos for research, 
it is permitted in the UK (both IVF and nuclear transfer)71, in 
Belgium (including SCNT)72 and in Spain73. It is forbidden, however, 
71  The Human Fertilization and Embryology (HFE) Act (2008). See 
http://www.opsi.gov.uk/acts/acts2008/ukpga_20080022_en_1  You can see also 
www.dh.gov.uk/en/Publicationsandstatistics/PublicationsLegislation/DH_080205  
72  The Law of 11 May 2003 Concerning research on embryos in vitro states in Article 6: 
"Human reproductive cloning is prohibited". Article 3 allows research on embryos in vitro 
for therapeutic purposes as well as for scientific research only where no other method of 
comparable efficacy is available and under strict conditions, notably if research takes place 
in laboratories accredited university with local and federal oversight on embryos within 
their first 14 days of development. Article 4 prohibits the creation of embryos for research 
purposes, except where supernumerary embryos will not meet research objectives, and 
subject to the same strict conditions applicable to embryos in vitro under Article 3. See 
http://unesdoc.unesco.org/images/0013/001342/134277e.pdf  
73  Art. 33 Law 14/2007, July 3 of Biomedical Research, vetoed the establishment of pre-
embryos and human embryos solely for experimental purposes, but allows the use of any 
technique for obtaining human stem cells for therapeutic or research which does not 
involve the creation of a pre-embryo or an embryo solely for this purpose, as defined by 
law, including activation of eggs by nuclear transfer. 
51 
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in Austria74, Denmark (including SCNT)75 and France76. It is also 
prohibited the creation of embryos for research in Germany 
(including the technique of SCNT)77 while the investigation is 
allowed under certain criteria; it is allowed under requisites in Greece 
(including SCNT), Ireland (including SCNT), Italy (including SCNT), 
74  In Austria the embryonic stem cell research is not permitted, and is regulated by 
legislation on assisted reproduction. See the following address: www.ris.bka.gv.at  / 
Bundesrecht 
75  Act on Medically Assisted Procreation 1997, as amended in 2003. See the following 
address: www.biokemi.org/biozoom/issues/498/articles/2060. They have a Centre for Stem 
Cell Research, see http://dasc.dk/ 
76  France began to legislate before the Directive was adopted, in July 1994 with a Iaw 
prohibiting patenting the human body or any of its parts, components or products, for 
reasons of public order and morality. See Richard GOLD and Alain GALLOCHAT: "The 
European Biotech Directive: Past and Prologue", op. cit. p. 340. In vitro fertilization could 
have only one purpose: to help a couple have a son. Embryos Ieft over were stored in a 
frozen state for five years for possible later implantation in the uterus of the mother. 
Parents could also decide to donate to another couple or to have them destroyed. After this 
period of five years, they had to be destroyed. Currently, the new French Iaw on bioethics 
passed with the end date of February 6, 2006 continues to prohibit the creation of embryos 
for research (including the technique of SCNT), while the situation has changed in other 
ways: allows licenses to import human embryonic stem cell lines, for a period of 5 years. 
See www.stencellconsortium.org. See also www.agence-biomedecine.fr  
77  Under the terms of paragraph 1 of "Embryo" (Embryo Protection Act) 1991 in Germany 
any person could be prosecuted if an egg is fertilized for any purpose other than to cause a 
pregnancy in the same woman who donated the egg. Thus, it was illegal to create an 
embryo for medica) research purposes. Currently research is permitted under HESTCs 
using criteria set by the German Stem Cell Act of 2002, with the amendments introduced 
in 2008. Accordingly, only those stem cell lines created before 1 May 2007 may be used for 
research. It also allows the import of HESC lines. 
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Netherlands and Portugal. Finland has no Iaw allowing or banning 
the technique of somatic nuclear transfer, but allows the derivation 
of stem cells from leftover embryos in vitro. 
Regarding the use of embryos for research is allowed in 
countries like Belgium, France, Spain and the United Kingdom. It is 
fforbidden, by contrast, in Austria. Finally, the derivation of 
embryonic stem cells is allowed for surplus embryos from assisted 
reproduction in Finland78, Greece, Holland, Sweden, United 
Kingdom, Belgium, Denmark, France, and Spain. Forbidden, but 
permitted the importation of cell lines in Germany and Italy. 
11.2.3 Significance of research purposes as regards 
patentability of results 
For the purposes of patentability, there is unanimity in the idea 
that the purpose of the invention must be lawful. The importance of 
the purpose intended is critical from the standpoint of protecting the 
results obtained. It now is part of the public policy clause of Art. 
6.2.c) of the Directive and has a greater importance. 
From the perspective of general interest pursued by the use of 
embryonic cells, it can improve the health of people (speaking, then, 
78  Under the Act, the embryos remaining in the fertilization treatments can be used for 
research, provided that donors have given their written consent. The embryos are not 
implanted into an organism and must be destroyed within 14 days after fertilization. The 
eggs and sperm can be stored in liquid nitrogen for 15 years, for example in cases where a 
disease at an early stage of adulthood is causing infertility. After the period of 15 years, the 
eggs and sperm can no Ionger be used in the investigation and must be destroyed. 
53 
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for therapeutic use), or the reproduction of the species (called, in this 
case, reproductive purposes) when they are intended to be implanted 
in the uterus for a natural birth). Observing the public policy clause 
from this point of view, only the first destination is deemed 
admissible. There is a unanimous rejection of the second destination. 
Thus, the so-called "cloning" reproduction is considered contrary to 
human dignity, and as such, contrary to public order and morality. 
The therapy, however, enjoys in the Directive a broad scope of 
freedom for each of the Member States designed in its policy, 
according to internal public order. It is therefore left to each State to 
decide on stem cell research (given the pluralism of society) with two 
conditions: where it is permitted, ensure the protection of the 
embryo, and prohibit the creation of embryos for research purposes79 
because according to the European Group of Ethics, the creation of 
embryos for research represents a disturbing step in the use of 
human life like an instrument. 
If the optics of the general interest is passed to the particular 
interest of those who financed the activity, the patent by its very 
nature is directed at the commercialization of the results. It is 
79 The general rule, under which states in Article 15 of the Oviedo Convention of 4 April 
1997 for the Protection of Human Rights and Dignity of the Human Being with regard to 
the Application of Biology and Medicine, is that scientific research in the field of biology 
and medicine are carried out freely, "subject to the provisions of this Agreement and other 
legal provisions ensuring the protection of human beings". Art.18 under the heading 
"Research on embryos in vitro, provides: "1. When experimentation on embryos in vitro is 
permissible under the law, it shall ensure adequate protection of the embryo. 1. It prohibits 
the creation of human embryos for experimental purposes". 
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undeniable that the interest of funded research activity in a field like 
biotechnology, which requires large financial resources tú invest, is to 
obtain a monopoly on the patented results and commercially exploit 
the invention, either directly, or after Iicensing to a third party - so as 
to recover the costs invested. In this sense, despite the prevent 
economic interests in this area, the public policy clause would 
prevent the commercialization of the results, which is a political 
triumph against the big biotech companies, at Ieast for now, as a 
disincentive to research80. 
The fact of recognizing an area of freedom for each of the 
Member States to design its internal policy on embryonic stem cell 
research should not mislead the normative level of research activity 
with the patentability of the results. In other words, freedom is left to 
each State to design its policy on stem cells research; another thing is 
that, although allowed the research, the patentability and the 
commercialization of the results would be prohibited. The fact that 
the Directive classifies non-patentable inventions contrary to public 
order causes not only that national regulations draw up a list of the 
same classifications, but also a list of prohibited commercial 
exploitations. In other words: they cannot establish a list of patenting 
80  The Warf case drew international attention as it could reduce substantially the 
opportunities for companies to commercialize stem cell related inventions through patent 
monopolies. Remarks by Gareth MORGAN, a lawyer specializing in intellectual property 
from Taylor Wessing LLP (London). Font used: Biotech Business Week, July 7, 2008, "Stem 
cell research; EPO highest authority to consider stem cell patents", Section: EXPANDED 
REPORTING; p.2563. See also The Scotsman, May 19, 2008, Monday, 1 Edition. "Stem cell 
sector awaits patent ruling", by Peter Ranscombe Business Reporter. Section: p. 28. 
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prohibitions for reasons of public order if not accompanied by a 
sanction of the exploitation of these inventions in their respective 
territories. 
However, some European legal systems distinguish the effects 
of patenting on the basis that embryonic cells have been created for 
research purposes or for marketing purposes, accepting the 
patentability of the former and excluding the latter. Is there any point 
for distinguishing between commercial or industrial purposes and 
research purposes, to exclude from patentability the first, and accept 
patents on embryonic stem cells that are directed to research? Does it 
make sense to patent a non-market outcome after the invention? 
What advantage carnes patent ownership of the invention if it 
cannot be marketed for reasons of public policy? In my view, this can 
only be understood as a key claim to acquire the rights to payment of 
royalties arising from the ownership of research for when, in the 
future marketing is allowed. 
The Directive 44/98 prohibits the patenting of inventions that 
have used human embryos for industrial or commercial purposes. In 
general, the prohibition of patenting may be due to two legislative 
policy objectives, which I consider necessary to clarify: they can 
prohibit the patenting of discouraging research and production of a 
certain field, or leave it to individuals building processes of the 
invention when they are very cheap, without forcing them to pay 
royalties. Which one of these objectives should be banned? The 
answer is none other than the first, discouraging research and 
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production, because it is known that the Directive represented a new 
configuration of a European patent in ethical issues but it is only the 
beginning and not the end of the discussions81. The public order 
clause that prohibits the patenting of the human embryos with 
commercial purposes was established in the Directive to discourage 
research and production in this area. However, it is not clear that alI 
countries will remain consistent with this legislative policy. 
Firstly, the prohibition of the use of human embryos for 
research or therapeutic purposes doesn't always go together with the 
prohibition of marketing. Germany, for example, prohibits the 
derivation of hESCs (except those created before 1 May 2007), but 
allows the importation (as much as the commercialization) of HESC 
lines82, and the same happens in Italy. 
81  Richard GOLD and Alain GALLOCHAT, op. cit., p. 347 
82  In Germany studies in the field of human embryonic stem cell research are regulated by 
the Embryo Protection Act (EschG) from 1990 and the Stem Cell Act ( "Law to Ensure the 
Protection of Embryos in Connection with the Importation and Use of Human Embryonic 
Stem Cells" [StZG] from 2002, modified in 2008). According to the Embryo Protection Act, 
the establishment of human embryonic stem cell (hESC) lines in Germany is prohibited by 
criminal sanctions. As an exception, hESC lines that were established in foreign countries 
before 01 May 2008 may be imported to Germany for research purposes (regulated by the 
Stem Cell Act). Such lines must have been established from "supernumerary" I VF embryos. 
This means from such embryos that were generated for purposes of reproduction, but no 
longer can be transferred to a woman. The evaluation is undertaken by an interdisciplinary 
"Central Ethics Committee for Stem Cell Research (LES) composed of natural scientists, 
medical researchers and humanities scholars. It proceeds In accordance with the StZG and 
the resulting opinions are forwarded to the Robert Koch Institute which makes the final 
decision concerning the applications. On 10 November 2006 DFG released its statement 
"Stem Cell Research in Germany - Possibilities and Perspectives" with the aim To improve 
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Moreover, some jurisdictions that allow the derivation of 
embryos for scientific purposes and for ethical reasons prohibit the 
marketing, according with the literal sense of the Directive. Would it 
make sense then that the results of research could be patented with 
the means to achieve a monopoly of ownership of research even if the 
commercialization was prohibited? Of course this does not seem very 
encouraging from the standpoint of investment, but in any case, 
there are jurisdictions that expressly permit it. Switzerland, for 
example, where the public order clause does not apply if the 
exploitation of embryos has research purposes (and expressly 
recognized this in their patent law)83. The patent is exciuded only 
when the operation has commercial or industrial purposes. In my 
opinion, the commercialization of the invention is a natural element 
the basic conditions for stem cell research. On 14 August 2008 the German Parliament 
modified the stem cell act and made the following changes: - The qualifying date (deadline) 
for the import of hES cell lines was moved from 01 January 2002 to 01 May 2007, Allowing 
the import of hESC lines generated before May 2007. - The threat of criminal sanctions for 
German scientists and the scope of the Stem Cell Act has been limited to activities Carried 
out in Germany. Since the Stem Cell Act has come into force, 40 research applications (7 
April 2009 status) for the importation of hESC lines have been approved (current list at 
http://www.rki.de). Nine of these hESC applications included the use of which would not 
have been permitted by the old 2002 version of the Stem Cell Act with the old qualifying 
date 01. January 2001. DFG is continuing its support for stem cell science. This year there 
is a joint call between the Chinese NSFC and DFG being evaluated addressing basic 
principies of stem cell biology. I nformation obtained from 
www.stemceliforum.org/about_theiscf/members/deutsche_forschungsgemeinschaft.cfm  
83  The possibility of patenting the uses of embryos for research is complemented by an 
open system of the obtained results to the public, establishing the need to publish the 
results of research carried out in subordinate employment and public funds. 
of the patent to recover the costs for investment, so it makes no sense 
to patent only for the purposes of research84. The only consistent 
explanation I can find is the allowing of patenting of ownership of 
research, and therefore we have an eye on possible future changes in 
the rule allowing the marketing of embryos, and eventually, having 
acquired the rights to payment of royalties for the licensing of 
exploitation. 
11.3. Ethical implications 
The real problem as regards the public order clause acting as a 
limitation for the patentability is to identify what exactly an embryo 
is. 
Obtaining stem cells from human embryos creates the ethical 
problem that the embryo must be destroyed to extract its inner cell 
mass, because so far science has failed to obtain cells from the 
blastocyst without destroying the structure that surrounds it85. The 
problems about what it means to be human in a pluralistic society 
84  The distinction between research and marketing does not make sense for EPO. The 
reason is that just as he hoids a patent for a product has the right to third parties shall not 
use or produce the product without its consent, the claim of the product involves its 
possible commercial or industrial exploitation, notwithstanding the intent of the patent 
appiicant may be another, like using the product for future research. EPO decision, Case G 
0002/06: "... as someone having a patent application with a claim directed to this product 
has on the grant of the patent the right to exclude others from making or using such 
product, making the commercial or industrial product remains exploitation of the 
invention even where there is an intention to use that product for further research....". 
85  BERIAI N, La donación, diez años después, Granada 2008, op. cit. 
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like Europe are large, as noted by Geertrui VAN OVERWALLE. 
Some authors consider that non-viable embryos, which do not lead 
to a birth, such as those created by parthenogenesis, or by somatic 
cell nuclear transfer (cloning) are not covered by the exclusion. 
Others believe that the use of embryos that involves their destruction 
is contrary to human dignity86. 
There are also those who oppose to the creation of surplus 
embryos with the means of investigation but don't find a problem 
using the surplus embryos from IVF, or importing cell lines produced 
in other countries, or simply the extraction, if possible, the cells from 
the blastocyst for this purpose87. The issue is the question. 
BERIAI N88, quoting two major supporters of this thesis: United 
States of America and Germany: "In both cases the moral 
background becomes the same: it is wrong to destroy embryos to 
create stem cells, but once they exist, it would be a gross 
irresponsibility not to benefit from them for the advancement of life 
sciences. In USA, the ban on embryo experimentation using public 
funds did not extend to the embryonic cell lines already in existence, 
86  VAN OVERWALLE, G.: "Patentability of human stem cells and cell lines", in "The Ethics 
of Patenting human genes and stem cells." Conference Report and Summaries. Held in 
Copenhagen 28 September 2004, Organized by The University of Copenhagen. The Danish 
Counci I of Ethics Biotika. www.biotik.dk/sw293.asp. p. 21. 
87 BERIAI N, La clonación, diez años después, op. cit., p. 104. 
88  An example: the WARF arguments before the EPO, which stated that the patents that 
claim the current use of human embryos should be rejected as contrary to morality, but not 
claiming a product derived from human embryonic cells, although primordial origin wrap 
isolate the product destroys the embryo. 
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nor to those created through private funding. In Germany, 
meanwhile, though it is forbidden to create embryos for these 
purposes, it is possible, although subject to many restrictions, to 
import cell lines obtained in other countries"89. 
Opponents to this argument think that the two events are 
inseparable from a moral standpoint, because they belong to a single 
set: If one creates embryo cell lines it's only because he wants to use 
them for research, and vice versa, if one uses these lines, he knows 
that they have been generated for this purpose. If Germany prohibits 
the destruction of embryos, but allows the import of lines created in 
other countries it is because they think that would be enough to 
continue with their research. In the U.S the possibility of the public 
research projects to buy cell lines generated with private funding 
hidden in the investment of the creation of these lines90. 
89  BERIAI N, La clonación, diez años después, op. cit., pp. 106 y 107: The advocates of this 
hypothesis argue that if a teenager is killed, that should not stop us when we need to use 
their organs to save other lives, because nobody in their right mind would believe that this 
will increase violence against adolescente. His view therefore is that one can distinguish 
between two different acts, destruction of the embryo and the use of their cells, and both 
are likely to be classified as morally independent. 
9° 
On August 9, 2001, President Bush banned the expenditure of public funds for research 
in HESTCs from that date on the basis that blastocysts have a moral equivalent of people. 
For Russell KOROBK IN, ("Recent Development in the "Stem Cell Century: Implications 
for Embryo Research, Egg Donor Compensation, and Stem Cell Patents in Jurimetrics, Vol 
49, No .1, 2008, pp. 51-71, op. cit. pp. 53, 56) the potential of embryonic stem cell research 
justifies the investment of public funds, regardless of the consequences that arise for 
embryos used in the creation of cell lines and the circumstances in which such embryos 
were created, unable to defend the position that blastocysts have a moral equivalent to that 
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11.4. Towards a redefinition of Human embryos 
On the other hand, new biotechnological inventions have 
helped to focus the terms of debate, not on whether or not the 
embryo is a person, but whether the technique is able to generate 
embryos. 
If we look at the Spanish legislation, it's noted that they sought 
to carefully preserve the traditional biological definition of embryo, 
considering as such the result of the fertilization. Whi le it's true that 
opting for the unorthodox way of dividing this figure in two different 
concepts, that of the pre-embryo and the embryo itself91 Thus the 
concept is limited to the entity resulting from the merger of male and 
female gametic material unti I 56 days later92. 
It has been emphasized the need to promote a new definition 
of human embryo and characterize them not only by their origin but 
of humans. They have none of the attributes that give people a unique morality. Certainly 
worth a deference of treatment compared with adult tissues, but not as individuals. At this 
point, about respect and deference they deserve treatment, the blastocyst, it is worth 
noting the distinction between reality that destroys human embryos and research using cell 
lines derived from destroyed embryos. Just as the distinction between research on 
embryonic stem cell lines when derived from surplus embryos from in vitro fertilization 
(line respects are accepted), and the creation of embryos solely for research purposes (via 
less respectful of the blastocyst). 
91  BERIAIN, La clonación. Diez años después, op.cit., pp. 108-109. 
92  BERIAIN, "The concept of embryo in the Law 14/2007 of 3 July, biomedical research," in 
Salome ADROHER, Federico MONTALVO BIOSCA and JAASKELAINEN (Directors): 
Los avances del Derecho ante los avances de la Medicina, ed. Aranzadi, 2008, pp. 991 and 
on. 
by their inner qualities, namely its potential to become a person, as 
has been reflected in some laws, such as Germany, Belgium, the 
Netherlands, and Japan. Moreover, the prospect of cell structure, as 
pluripotent or totipotent is the decisive criterion for the purpose of 
research and patentability in the intellectual property office of the 
United Kingdom93. 
German law provides in its paragraph 3.4 a definition of 
embryo: "an embryo is any human totipotent cell that has the ability 
to divide and become a human individual provided that the required 
necessary conditions are met"94. In Belgium, the embryo is defined as 
a "cohesive cell or cell system with capacity to develop and lead to a 
human person"95. In the Netherlands as a "cell or group of cells with 
capacity to develop and become a human being"96. In Japan as "a cell 
- except a germ cell- or cells that can become an individual through 
their 	 development 
93  Go to the following address: http://www.ipo.gov.uk/pro-types/pro-patent/p-law/p-pn-
stemcells/2009203.htm  
94  Act respecting the protection of the embryo in relation to the importation and use of 
embryonic stem cells of human origin (Law of stem cells) of 28 June 2002. 
95  See Belgian Chamber of Representatives, Bill Concerning Research on Embryos in vitro, 
December 23, 2002. 
se See Kingdom of the Netherlands, Embryo Act, September 1, 2002. 
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in vitro of a human or animal, and has not yet begun the formation of 
the placenta"97. 
In summary, given the need to redefine the concept of embryo, 
the formula that has more adherences is using the concept of 
potentiality98, although, to avoid counter-intuitive (and impractical) 
ideas that sperm and human eggs are also people99, it is necessary to 
distinguish between the ideas of potentiality and possibility, and 
even, following BERIAIN, going beyond, it is feasible to differentiate, 
in fact, up to three concepts: active power, passive power and 
possibility. In this way, and using his words, an embryo in vitro has 
active power because simply it's not necessary to intervene, and it's 
enough to let nature take its course and develop into a person ...An 
embryo in vitro, in contrast, has only passive power because even if it 
contains sufficient information to create a human being is not in the 
right environment to do so. Finally, a embroider body, i.e. the result 
of failed fertilization, would have neither power nor possibility of 
creating a human being. 
Furthermore, the invention of the technique of somatic 
nuclear transfer has previously required stating if these nuclei of an 
97  The author, BERIAIN, op.cit.,1005, uses the transiation text from the Inter-University 
Chair BBVA Foundation-Provincial Government of Biscay in Law and Human Genome, 
Código de Leyes sobre Genética (II), Bilbao-Granada, ed. Comares, 2007. 
98  See BERIAIN, La clonación, diez anos después, op.cit, pp.113 and 117-120 for theories of 
the supporters of the ontogenesis and epigénesis. 
99 BERIAIN, op.cit., pp. 124 and on. 
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egg are human embryos or not. What kind of potential would they 
have? It appears that the current state of the ontological structure 
responds to a pluripotent cell, not totipotent, and therefore, "the vast 
majority of them do not have any potential to develop as 
individuals"100. So, they are not an embryo in a strict sense. 
One argument that has been recurrently used against 
techniques of nuclear stem cell transfers come from the need they 
have to use vast quantities of human eggs as the only means to create 
human cell fines. But the problem that arises is that it is too 
complicated to get the number of eggs needed because the removal 
from a woman's body is no longer just painful and uncomfortable, 
but also dangerous101. 
Two possible alternatives are mentioned by BERIAIN: Allow 
the economic consideration of the eggs (although in his view women 
would be subjected to unlawful harassment, even if they gave their 
informed consent). 102  Another alternative would be the use of eggs 
100  BERIAIN, op.cit., pp. 125-126, and 128. See also Osuna CARRILLO DE ALBORNOZ / 
Andreu MARTÍNEZ, "Investigación con preembriones. Comentario a los arts. 15 y 16 de la 
LTRHA", in Corbacho GOMEZ (dir.), Iniesta DELGADO (coord.) Comentarios a la Ley 
14/2006 de 26 Mayo de Técnicas de Reproducción Humana Asistida, Navarra 2007, pp. 483 
to 511. 
101  BERIAIN, La clonación, diez años después, op.cit., pp. 133 and on. 
102  In the U.S., given the narrow legal confines (The Human Cloning Prohibition Act, 2001) 
the technique could be illegal, regardless of funding source, but the Senate failed to clarify 
so that there is no federal legislation banning the cloning therapy, although some states 
have enacted laws expressly prohibiting it. The problem is different: since the technique 
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from other species through the creation of chimeras and hybrids 
between humans and animals103: "The problem with this solution is, 
however, that in the opinion of many, would be a serious attack on 
the dignity of the human species as a whole, and would most likely be 
rejected by the majority. From the opposite point of view however, it 
is conceivable that prohibiting this kind of research would be, at a 
time, a serious attack against the principie of beneficence, as it would 
deprive thousands of people the possibility of benefiting from their 
results. In another view, a loss of valuable opportunities to improve 
our understanding of how biological embryo and gamete 
mechanisms function. These arguments, in fact, have a very 
substantial importance that made the British government, after 
announcing its intention to prohibit the application of this kind of 
technology, to decide to turn back, and finally, to permit this kind of 
experiment, but subject to strict controls104. 
With respect to the use of other techniques, we must agree, 
following BERIAIN that creation of unfertilized egg cells and 
subsequent destruction for obtaining stem cells does not have any 
problem from an ethical standpoint105. In contrast, ANT, (Altered 
requires egg donation, experience shows that women are not willing to donate for free, 
since the Iaw in many of these States consider it unethical to pay for the eggs. 
103  BERIAIN, La donación, diez años después, op. cit., p.135. 
1°4  Cfr. http://www.hfea.gov.uk/en/1517.html  
105  BERIAIN, op. cit., p. 129. See pp. 48-49 for an explanation of the experiment. 
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Nuclear Transfer)106  to alter the structure of the resulting cell when 
it was set up as such, what it does is to destroy the once already 
constituted embryos, rather than avoid that they come to exist107. 
As regards the OAR (Oocyte Assisted Reprogramming)108, if 
this technique prevents the embryo from coming into being, the 
effect caused is to eliminate any potential before the appropriate 
conditions for the development. This fact removes all reasonable 
ethical doubt. Finally, the technique of iPS109 doesn't generate any 
serious ethical problems, because this technique relies on the 
alteration of genes in a somatic cell, in a way that it behaves as if it 
were a pluripotent ce11110. 
11.5. Conclusion 
In the way of conciuding ideas, summing up the questions 
analysed in this Chapter, we can put forward the following: 
First. The disparity of rules and criteria as to what can be 
patented, and with respect to embryonic stem cell research originates 
several implications. The first is that notwithstanding that there are 
alternative routes to European patent application, as demonstrated 
1°8  For an explanation of the method, pp. 49-51. 
107 Beriain, op.cit., p. 130. 
1°8  For a detailed explanation of the method, see pp. 51 and on. 
109  Description of the method on pp. 52 and on. 
110 BERIAIN, op.cit., p. 131. 
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by the UK - although rarely used, given the irony that the original 
motivation of the Directive, which was to ensure the hospitality of 
the laws of European patents for biotechnological inventions from 
other countries, not oniy has not been accomplished, but quite the 
opposite: the patents in USA, Korea, Japan and other countries 
outside Europe, cannot find a place in Europe. The question then is 
whether a single system would be desirable for biotechnology patents 
throughout Europe. Undoubtedly yes, but poor countries' firms in 
the sector (including Spain), are not in favor because by retaining the 
power to decide what is patentable and what not in this area, protects 
their own businesses, which would not be forced to pay large sums 
for the assignment of licenses for the exploitation of inventions in 
these areas. 
Second. lt seems evident the need for common ground for a 
proper definition of the term "embryo", which is a priority both for 
the legal practitioners as for researchers. This would clarify further 
the regime of patentability, which in my opinion, should not be 
excluded when embryonic stem cells have been created according to 
a method that has not destroyed embryos strictly, in order to 
improve the health of population. The patent can be extended to 
research and/or marketing111 . 
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Third. The need for an international code of stem cell research 
is the situation in Europe regarding standards for research on 
embryos and embryonic stem cells highlighting the great disparity in 
this field and the result of cultural diversity that exists in Europe. 
This should lead us to conciude the need to encourage a public 
debate on these issues. In this sense, it has been highlighted by 
Professor Bartha Maria KNOPPERS, the need for an international 
code of stem cell research, to help overcome the ethical barriers in 
this field of research112. Renowned scientists and organizations have 
signed the Charter of stem cells, writing that refers to the Charter of 
the World Health Organization 1946, which stipulates that 
"enjoyment of the highest attainable state of health is one of the 
fundamental rights of every human being without distinction of race, 
religion, and political belief, economic or social condition". To that 
end, the Stem Cell Charter upholds the following principies: 
1. Responsibility to maintain the highest level of scientific 
quality, safety and ethical probity. 
2. Protection of citizens from harm and safeguarding of the 
public trust and values. 
111  One of the challenges posed to the EPO, not explicitly resolved yet, had to do with 
technological innovations. Methods for generating stem cells from "non-viable" "triploid 
zygotes", the nuclear transfer technique abnormally creating blastocysts which can not 
implant in the uterus, but are capable of generating stem cells, or finally, the technique to 
produce stem cells through biopsy of an embryo in its own right, without interfering with 
the process their development, in recent years they raised the need to overcome the ethical 
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issues related to stem cell research and whether if the viability of the organism, id est, its 
potential to develop during pregnancy, is a necessary condition for classification as an 
embryo for that purpose, or whether the destruction of the embryo in the proper sense is a 
necessary condition to reject the patent. See "The patentability of human embryonic stem 
cells in Europe. Applicants in Europe are left with few options for the patent protection of 
hEScell-related technology", Nature Biotechnology, vol. 24, No 6, June 2006. 
112  See the text of the declaration www.stemcellecharter.org  
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3. Intellectual Freedom to exchange ideas in the spirit of 
international cooperation. 
4. Transparency through the disclosure of results and of 
possible conflicts of interest. 
5. Finally, Integrity in the promotion and advancement of 
stem cell research and therapy for the betterment of the 
welfare of all human beings. 
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